Hypertensive diseases and eclampsia.
Worldwide, pre-eclampsia and eclampsia contribute to the death of a pregnant woman every 3 min. In the UK in recent decades, hypertensive disorders of pregnancy have remained one of the leading causes of both maternal and perinatal morbidity and mortality. The management of pregnancies complicated by hypertension has not significantly altered for many years, possibly as a result of little progress being made in our understanding of the condition. New insights, however, have recently been gained into the pathophysiology of pre-eclampsia. These have yet to be translated into new interventions or to make any impact on clinical management of these pregnancies. This review will therefore focus on recent advances relating to research into the aetiology and pathogenesis of pre-eclampsia, but will conclude with a brief update on current therapeutic strategies.
Myers
Jenny E
JE
Maternal and Fetal Health Research Centre, St Mary's Hospital, Manchester, UK. jenny.myers@man.ac.uk
Baker
Philip N
PN
D000959:Antihypertensive Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D004461:Eclampsia / Q000209:etiology / Q000628:therapy; D016228:Endothelial Growth Factors / Q000502:physiology; D004730:Endothelium, Vascular / Q000502:physiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis; D008222:Lymphokines / Q000502:physiology; D011225:Pre-Eclampsia / Q000209:etiology / Q000628:therapy; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000175:diagnosis; D012307:Risk Factors; D014327:Trophoblasts / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000959:Antihypertensive Agents; D000975:Antioxidants; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D001241:Aspirin